Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease

Lawrence W Elmer; Jorge L Juncos; Carlos Singer; Daniel D Truong; Susan R Criswell; Sotirios Parashos; Larissa Felt; Reed Johnson; Rajiv Patni

doi:10.1007/s40263-018-0510-z

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease

CNS Drugs. 2018 Apr;32(4):399-400. doi: 10.1007/s40263-018-0510-z.

Authors

Lawrence W Elmer¹, Jorge L Juncos², Carlos Singer³, Daniel D Truong⁴, Susan R Criswell⁵, Sotirios Parashos⁶, Larissa Felt⁷, Reed Johnson⁷, Rajiv Patni⁷

Affiliations

¹ Department of Neurology, University of Toledo College of Medicine, 3120 Glendale Avenue, Toledo, OH, 43614, USA. Lawrence.Elmer@utoledo.edu.
² Department of Neurology and Movement Disorders, Emory University School of Medicine, Atlanta, GA, USA.
³ Department of Neurology, University of Miami, Miami, FL, USA.
⁴ The Parkinson's and Movement Disorder Institute, Fountain Valley, CA, USA.
⁵ Department of Neurology, Washington University, St. Louis, MO, USA.
⁶ Struthers Parkinson's Center, Golden Valley, MN, USA.
⁷ Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.

Abstract

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted.

Publication types

Published Erratum